ID

14118

Description

Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management; ODM derived from: https://clinicaltrials.gov/show/NCT01908075

Link

https://clinicaltrials.gov/show/NCT01908075

Keywords

  1. 3/30/16 3/30/16 -
Uploaded on

March 30, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Asthma NCT01908075

Eligibility Asthma NCT01908075

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01908075
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
aged: 18-80 years 61-80 years to be non-smokers only
Description

Age | Non-smoker

Data type

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0337672
evidence of asthma: a diagnostic code for asthma or two scripts for asthma..
Description

Asthma

Data type

boolean

Alias
UMLS CUI [1]
C0004096
baseline fp/sal therapy: ≥2 prescription for ics/laba therapy as fp/sal
Description

fluticasone | salmeterol | Therapeutic procedure | inhaled steroids | Adrenergic beta-2 Receptor Agonists | Therapeutic procedure

Data type

boolean

Alias
UMLS CUI [1,1]
C0082607
UMLS CUI [1,2]
C0073992
UMLS CUI [1,3]
C0087111
UMLS CUI [2,1]
C2065041
UMLS CUI [2,2]
C2936789
UMLS CUI [2,3]
C0087111
evidence of continuing therapy: include only patients who receive ≥2 prescriptions for the therapy under study during the outcome year (i.e. ≥1 prescription at the index date and ≥1 other). uk average is 3-4 prescriptions refilled per year, so ≥2 ensures capture of "real-life" data.
Description

Continuous therapeutic procedure | prescription

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0549178
UMLS CUI [2]
C1521941
evidence of switching for economic reasons: fp/sal patients from practices with ≥5 switches to fostair in a 3 month period to minimise data taken from switching of anomalous patients; optimal practices for inclusion are those switching "wholesale" for economic reasons.
Description

Therapy change | fluticasone salmeterol

Data type

boolean

Alias
UMLS CUI [1]
C3665894
UMLS CUI [2,1]
C0082607
UMLS CUI [2,2]
C0073992
UMLS CUI [2,3]
C0087111
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any chronic respiratory disease other than asthma
Description

Chronic disease of respiratory system

Data type

boolean

Alias
UMLS CUI [1]
C0264220
UMLS CUI [2]
C0004096
are receiving maintenance oral steroid therapy during baseline period
Description

Oral steroid therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0087111

Similar models

Eligibility Asthma NCT01908075

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01908075
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age | Non-smoker
Item
aged: 18-80 years 61-80 years to be non-smokers only
boolean
C0001779 (UMLS CUI [1])
C0337672 (UMLS CUI [2])
Asthma
Item
evidence of asthma: a diagnostic code for asthma or two scripts for asthma..
boolean
C0004096 (UMLS CUI [1])
fluticasone | salmeterol | Therapeutic procedure | inhaled steroids | Adrenergic beta-2 Receptor Agonists | Therapeutic procedure
Item
baseline fp/sal therapy: ≥2 prescription for ics/laba therapy as fp/sal
boolean
C0082607 (UMLS CUI [1,1])
C0073992 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C2065041 (UMLS CUI [2,1])
C2936789 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
Continuous therapeutic procedure | prescription
Item
evidence of continuing therapy: include only patients who receive ≥2 prescriptions for the therapy under study during the outcome year (i.e. ≥1 prescription at the index date and ≥1 other). uk average is 3-4 prescriptions refilled per year, so ≥2 ensures capture of "real-life" data.
boolean
C0087111 (UMLS CUI [1,1])
C0549178 (UMLS CUI [1,2])
C1521941 (UMLS CUI [2])
Therapy change | fluticasone salmeterol
Item
evidence of switching for economic reasons: fp/sal patients from practices with ≥5 switches to fostair in a 3 month period to minimise data taken from switching of anomalous patients; optimal practices for inclusion are those switching "wholesale" for economic reasons.
boolean
C3665894 (UMLS CUI [1])
C0082607 (UMLS CUI [2,1])
C0073992 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Chronic disease of respiratory system
Item
any chronic respiratory disease other than asthma
boolean
C0264220 (UMLS CUI [1])
C0004096 (UMLS CUI [2])
Oral steroid therapy
Item
are receiving maintenance oral steroid therapy during baseline period
boolean
C0001617 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial